Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

Li, Xiang; Chen, Xian-Xin; Xu, Yu; Xu, Xianbing; Wu, Wenfei; Zhao, Qi; Hu, Jiang‐Ning

doi:10.1021/acs.biomac.1c01360

Cited by 12 publications

(7 citation statements)

References 58 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the experiment, multiple doses of resveratrol were extracted for dosage analysis. Meanwhile, only the information of high dose groups was refined for comparison ( Li et al, 2022a ). Regarding continuous variables usually displayed as graph, WebPlotDigitizer was applied to extract the mean score and standard deviation (SD) from both intervention and model groups.…”

Section: Methodsmentioning

confidence: 99%

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

He,

Li,

Deng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Resveratrol, a polyphenol found in various plants, is known for its diverse bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD). However, no high-quality evidence exists regarding its efficacy.Objective: a meta-analysis was conducted to evaluate the potential efficacy of resveratrol in treating nonalcoholic fatty liver disease by analyzing both preclinical studies and clinical trials.Method: PubMed, Embase and Web of Science were searched for the included literature with the criteria for screening. Quantitative synthesis and meta-analyses were performed by STATA 16.0.Results: Twenty-seven studies were included, and the results indicated that resveratrol effectively improved liver function, reduced fatty liver indicators, and affected other indices in preclinical studies. The effective dosage ranged from 50 mg/kg-200 mg/kg, administered over a period of 4–8 weeks. While there were inconsistencies between clinical trials and preclinical research, both study types revealed that resveratrol significantly reduced tumor necrosis factor-α levels, further supporting its protective effect against nonalcoholic fatty liver disease. Additionally, resveratrol alleviated nonalcoholic fatty liver disease primarily via AMPK/Sirt1 and anti-inflammatory signaling pathways.Conclusion: Current meta-analysis could not consistently verify the efficacy of resveratrol in treating nonalcoholic fatty liver disease, but demonstrated the liver-protective effects on nonalcoholic fatty liver disease. The large-sample scale and single region RCTs were further needed to investigate the efficacy.

show abstract

Section: Methodsmentioning

confidence: 99%

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

He,

Li,

Deng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Each tube had a diameter of 25 mm, a height of 96 mm, and a volume of 20 mL. Glycogen-iodine mixture samples were prepared as follows: 33 samples were prepared from three groups (Groups A, B, and C) of homogeneous glycogen (BR, 99% extracted from mussel, Source Leaf Creatures)-water mixed samples with a glycogen concentration gradient of 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 mg/mL (corresponding glycogen weight-to-water weight ratio: 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%) ( 15 ). The glycogen concentration was configured based on the in vivo hepatic glycogen content, which could reach 10% under certain pathological conditions ( 16 , 17 ).…”

Section: Methodsmentioning

confidence: 99%

Harnessing dual-energy CT for glycogen quantification: a phantom analysis

Li¹,

Li²,

Wei³

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background Non-invasive glycogen quantification in vivo could provide crucial information on biological processes for glycogen storage disorder. Using dual-energy computed tomography (DECT), this study aimed to assess the viability of quantifying glycogen content in vitro . Methods A fast kilovolt-peak switching DECT was used to scan a phantom containing 33 cylinders with different proportions of glycogen and iodine mixture at varying doses. The virtual glycogen concentration (VGC) was then measured using material composition images. Additionally, the correlations between VGC and nominal glycogen concentration (NGC) were evaluated using least-square linear regression, then the calibration curve was constructed. Quantitative estimation was performed by calculating the linearity, conversion factor (inverse of curve slope), stability, sensitivity (limit of detection/limit of quantification), repeatability (inter-class correlation coefficient), and variability (coefficient of variation). Results In all conditions, excellent linear relationship between VGC and NGC were observed (P<0.001, coefficient of determination: 0.989–0.997; residual root-mean-square error of glycogen: 1.862–3.267 mg/mL). The estimated conversion factor from VGC to NGC was 3.068–3.222. In addition, no significant differences in curve slope were observed among different dose levels and iodine densities. The limit of detection and limit of quantification had respective ranges of 6.421–15.315 and 10.95–16.46 mg/mL. The data demonstrated excellent scan-repeat scan agreement (inter-class correlation coefficient, 0.977–0.991) and small variation (coefficient of variation, 0.1–0.2%). Conclusions The pilot phantom analysis demonstrated the feasibility and efficacy of detecting and quantifying glycogen using DECT and provided good quantitative performance with significant stability and reproducibility/variability. Thus, in the future, DECT could be used as a convenient method for glycogen quantification to provide more reliable information for clinical decision-making.

show abstract

“…Cell Uptake. The ability of cell internalization was investigated based on the method of Li et al 33 The HepG2 cells were grown in cells climbing and incubated at 37 °C for 12 h. Then, the cell was treated with FITC-PT NPs for 2 and 4 h, respectively. After the cell was washed and fixed in 4% paraformaldehyde for 20 min.…”

Section: Antioxidant Efficiency Of Pt Npsmentioning

confidence: 99%

Construction of Phlorotannin-Based Nanoparticles for Alleviating Acute Liver Injury

Luo,

Zhu,

et al. 2023

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Acute liver injury (ALI) is a severe health condition with limited treatment options. Phlorotannin (PT), a natural compound extracted from seaweeds, has shown potential in improving liver function. However, its poor stability and bioavailability have limited its applications in vivo. In this study, we developed PT-based nanoparticles (NPs) through a Mannich reaction with glycine, which exhibited good biocompatibility and prolonged circulation time in vivo. Our results revealed that the PT NPs possess strong free radical scavenging ability, effectively reducing reactive oxygen species (ROS) and alleviating oxidative stress and proinflammatory responses in the H 2 O 2 -induced oxidative damage model of HepG2 cells. Furthermore, the PT NPs effectively attenuated oxidative stress and inflammation in the liver tissue of carbon tetrachloride (CCl 4 )-induced liver injury mice by regulating the Nrf2/HO-1 signaling pathway. In summary, our results suggested that the PT NPs could serve as a promising nano-therapeutic strategy for alleviating ALI.

show abstract

Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

Cited by 12 publications

References 58 publications

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

Harnessing dual-energy CT for glycogen quantification: a phantom analysis

Construction of Phlorotannin-Based Nanoparticles for Alleviating Acute Liver Injury

Contact Info

Product

Resources

About